메뉴 건너뛰기




Volumn 71, Issue 11, 2011, Pages 1469-1480

Romidepsin: In the treatment of T-cell lymphoma

Author keywords

Adis Drug Profiles; Romidepsin, General; T cell lymphoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ATAZANAVIR; CARBAMAZEPINE; CARBOPLATIN; CLARITHROMYCIN; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; NEFAZODONE; NELFINAVIR; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; RIFAPENTINE; RITONAVIR; ROMIDEPSIN; ROMIPLOSTIM; SAQUINAVIR; TELITHROMYCIN; VORICONAZOLE; VORINOSTAT; WARFARIN;

EID: 79961134336     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11207170-000000000-00000     Document Type: Review
Times cited : (28)

References (53)
  • 2
    • 70349739368 scopus 로고    scopus 로고
    • Update on the World Health Organization classification of peripheral T-cell lymphomas
    • Oct
    • O'Leary HM, Savage KJ. Update on the World Health Organization classification of peripheral T-cell lymphomas. Curr Hematol Malig Rep 2009 Oct; 4 (4): 227-35.
    • (2009) Curr Hematol Malig Rep , vol.4 , Issue.4 , pp. 227-235
    • O'Leary, H.M.1    Savage, K.J.2
  • 4
    • 0346095263 scopus 로고    scopus 로고
    • Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas
    • DOI 10.1111/j.1365-2133.2003.05698.x
    • Whittaker SJ, Marsken JR, Spittle M, et al. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003 Dec; 149 (6): 1095-107. (Pubitemid 38058085)
    • (2003) British Journal of Dermatology , vol.149 , Issue.6 , pp. 1095-1107
    • Whittaker, S.J.1    Marsden, J.R.2    Spittle, M.3    Russell Jones, R.4
  • 5
    • 33646398594 scopus 로고    scopus 로고
    • EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome
    • May
    • Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006May; 42 (8): 1014-30.
    • (2006) Eur J Cancer , vol.42 , Issue.8 , pp. 1014-1030
    • Trautinger, F.1    Knobler, R.2    Willemze, R.3
  • 6
    • 38349074221 scopus 로고    scopus 로고
    • Management of advanced-stage peripheral T-cell lymphomas
    • Oct
    • Kimby E. Management of advanced-stage peripheral T-cell lymphomas. Curr HematolMalig Rep 2007 Oct; 2 (4): 242-8.
    • (2007) Curr HematolMalig Rep , vol.2 , Issue.4 , pp. 242-248
    • Kimby, E.1
  • 7
    • 51649091675 scopus 로고    scopus 로고
    • International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. International T-Cell Lymphoma Project
    • Sep 1
    • Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. International T-Cell Lymphoma Project. J Clin Oncol 2008 Sep 1; 26 (25): 4124-30.
    • (2008) J Clin Oncol , vol.26 , Issue.25 , pp. 4124-4130
    • Vose, J.1    Armitage, J.2    Weisenburger, D.3
  • 9
    • 71249097862 scopus 로고    scopus 로고
    • Management of T-cell and natural-killer-cell neoplasms in Asia: Consensus statement from the Asian Oncology Summit 2009
    • Nov
    • Kwong YL, Anderson BO, Advani R, et al. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009 Nov; 10 (11): 1093-101.
    • (2009) Lancet Oncol , vol.10 , Issue.11 , pp. 1093-101
    • Kwong, Y.L.1    Anderson, B.O.2    Advani, R.3
  • 10
    • 77955425848 scopus 로고    scopus 로고
    • Peripheral T-cell lymphoma: Autologous hematopoietic cell transplanation as first-line therapy
    • Sep
    • Laport GG. Peripheral T-cell lymphoma: autologous hematopoietic cell transplanation as first-line therapy. Curr Opin Oncol 2010 Sep; 22 (5): 409-13.
    • (2010) Curr Opin Oncol , vol.22 , Issue.5 , pp. 409-413
    • Laport, G.G.1
  • 11
    • 79961133356 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors in oncology
    • Chabner BA, Longo DL, editors Philadelphia (PA): Lippincott Williams & Wilkins
    • Rahman F, Robey RW, Bates SE, et al. Histone deacetylase inhibitors in oncology. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2011: 442-58.
    • (2011) Cancer Chemotherapy and Biotherapy: Principles and Practice. 5th Ed , pp. 442-458
    • Rahman, F.1    Robey, R.W.2    Bates, S.E.3
  • 12
    • 73949128107 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors in cancer therapy
    • Nov 10
    • Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009 Nov 10; 27 (32): 5459-68.
    • (2009) J Clin Oncol , vol.27 , Issue.32 , pp. 5459-5468
    • Lane, A.A.1    Chabner, B.A.2
  • 13
    • 77349115530 scopus 로고    scopus 로고
    • Current and emerging treatment strategies for cutaneous T-cell lymphoma
    • Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70 (3): 273-86.
    • (2010) Drugs , vol.70 , Issue.3 , pp. 273-286
    • Lansigan, F.1    Foss, F.M.2
  • 14
    • 70349100446 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Current status and overview of recent clinical trials [published erratum appears
    • Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials [published erratum appears in Drugs 2009; 69 (15): 2102.
    • (2009) Drugs , vol.69 , Issue.15 , pp. 2102
    • Ma, X.1    Ezzeldin, H.H.2    Diasio, R.B.3
  • 15
    • 67449138841 scopus 로고    scopus 로고
    • Epigenetic modifiers: Basic understanding and clinical development
    • Jun 15
    • Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009 Jun 15; 15 (12): 3918-26.
    • (2009) Clin Cancer Res , vol.15 , Issue.12 , pp. 3918-3926
    • Piekarz, R.L.1    Bates, S.E.2
  • 17
    • 84856624942 scopus 로고    scopus 로고
    • Merck Sharp & Dohme Corp [Accessed 2011 Jul 6]
    • Merck Sharp & Dohme Corp. Zolinza (vorinostat) capsules: US prescribing information [online]. Available from URL: http://www.merck.com/ product/usa/pi-circulars/z/zolinza/zolinza-pi.pdf [Accessed 2011 Jul 6].
    • Zolinza (Vorinostat) Capsules: US Prescribing Information [Online]
  • 18
    • 0028258610 scopus 로고
    • FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity
    • Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994 Mar; 47 (3): 301-10. (Pubitemid 24106520)
    • (1994) Journal of Antibiotics , vol.47 , Issue.3 , pp. 301-310
    • Ueda, H.1    Nakajima, H.2    Hori, Y.3    Fujita, T.4    Nishimura, M.5    Goto, T.6    Okuhara, M.7
  • 20
    • 77249087051 scopus 로고    scopus 로고
    • Chemical phylogenetics of histone deacetylases
    • Mar
    • Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010 Mar; 6 (3): 238-43.
    • (2010) Nat Chem Biol , vol.6 , Issue.3 , pp. 238-243
    • Bradner, J.E.1    West, N.2    Grachan, M.L.3
  • 21
    • 79952396960 scopus 로고    scopus 로고
    • Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
    • Mar
    • Bantscheff M, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011 Mar; 29 (3): 255-65.
    • (2011) Nat Biotechnol , vol.29 , Issue.3 , pp. 255-265
    • Bantscheff, M.1    Hopf, C.2    Savitski, M.M.3
  • 22
    • 78651352243 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Potential targets responsible for their anticancer effect
    • Dec
    • Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anticancer effect. InvestNewDrugs 2010Dec; 28 Suppl. 1: S3-20.
    • (2010) Invest New Drugs , vol.28 , Issue.SUPPL.1
    • Dickinson, M.1    Johnstone, R.W.2    Prince, H.M.3
  • 23
    • 0033639025 scopus 로고    scopus 로고
    • Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells
    • Nov
    • Murata M, Towatari M, Kosugi H, et al. Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. Jpn JCancerRes 2000 Nov; 91 (11): 1154-60.
    • (2000) Jpn JCancerRes , vol.91 , Issue.11 , pp. 1154-1160
    • Murata, M.1    Towatari, M.2    Kosugi, H.3
  • 25
    • 2942535832 scopus 로고    scopus 로고
    • T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: Impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance
    • DOI 10.1182/blood-2003-09-3068
    • Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004 Jun 15; 103 (12): 4636-43. (Pubitemid 38745996)
    • (2004) Blood , vol.103 , Issue.12 , pp. 4636-4643
    • Piekarz, R.L.1    Robey, R.W.2    Zhan, Z.3    Kayastha, G.4    Sayah, A.5    Abdeldaim, A.H.6    Torrico, S.7    Bates, S.E.8
  • 26
    • 72649091422 scopus 로고    scopus 로고
    • Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
    • Jan
    • Bates SE, Zhan Z, Steadman K, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010 Jan; 148 (2): 256-67.
    • (2010) Br J Haematol , vol.148 , Issue.2 , pp. 256-267
    • Bates, S.E.1    Zhan, Z.2    Steadman, K.3
  • 28
    • 79952394059 scopus 로고    scopus 로고
    • The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells
    • Apr
    • Tiffon C, Adams J, van der Fits L, et al. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol 2011 Apr; 162 (7): 1590-602.
    • (2011) Br J Pharmacol , vol.162 , Issue.7 , pp. 1590-602
    • Tiffon, C.1    Adams, J.2    Van Der Fits, L.3
  • 29
    • 0028267278 scopus 로고
    • FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice
    • Ueda H, Manda T, Matsumoto S, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. III. Antitumor activities on experimental tumors inmice. J Antibiot (Tokyo) 1994 Mar; 47 (3): 315-23. (Pubitemid 24106522)
    • (1994) Journal of Antibiotics , vol.47 , Issue.3 , pp. 315-323
    • Ueda, H.1    Manda, T.2    Matsumoto, S.3    Mukumoto, S.4    Nishigaki, F.5    Kawamura, I.6    Shimomura, K.7
  • 30
    • 79953725710 scopus 로고    scopus 로고
    • Deciphering the molecular and biological processes that mediate histone deacetylase inhibitor-induced thrombocytopenia
    • Mar 31
    • Bishton MJ, Harrison SJ, Martin BP, et al. Deciphering the molecular and biological processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2011 Mar 31; 117 (13): 3658-68.
    • (2011) Blood , vol.117 , Issue.13 , pp. 3658-3668
    • Bishton, M.J.1    Harrison, S.J.2    Martin, B.P.3
  • 32
    • 23044440043 scopus 로고    scopus 로고
    • Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)- ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6] -tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines
    • DOI 10.1124/jpet.105.083956
    • Xiao JJ, Huang Y, Dai Z, et al. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-di-isopropyl-2-oxa-12,13-dithia-5, 8,20,23-tetraazabi-cyclo [8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther 2005 Jul; 314 (1): 467-75. (Pubitemid 41058285)
    • (2005) Journal of Pharmacology and Experimental Therapeutics , vol.314 , Issue.1 , pp. 467-475
    • Xiao, J.J.1    Huang, Y.2    Dai, Z.3    Sadee, W.4    Chen, J.5    Liu, S.6    Marcucci, G.7    Byrd, J.8    Covey, J.M.9    Wright, J.10    Grever, M.11    Chan, K.K.12
  • 33
    • 67449127083 scopus 로고    scopus 로고
    • Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: Mechanisms and potential clinical implications
    • Jun 15
    • Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009 Jun 15; 15 (12): 3947-57.
    • (2009) Clin Cancer Res , vol.15 , Issue.12 , pp. 3947-3957
    • Schrump, D.S.1
  • 34
    • 33645069138 scopus 로고    scopus 로고
    • Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)
    • Mar 1
    • Robey RW, Zhan Z, Piekarz RL, et al. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 2006 Mar 1; 12 (5): 1547-55.
    • (2006) Clin Cancer Res , vol.12 , Issue.5 , pp. 1547-1555
    • Robey, R.W.1    Zhan, Z.2    Piekarz, R.L.3
  • 35
    • 67650296574 scopus 로고    scopus 로고
    • Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities
    • Jun
    • Dedes KJ, Dedes I, Imesch P, et al. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs 2009 Jun; 20 (5): 321-33.
    • (2009) Anticancer Drugs , vol.20 , Issue.5 , pp. 321-333
    • Dedes, K.J.1    Dedes, I.2    Imesch, P.3
  • 36
    • 73949149251 scopus 로고    scopus 로고
    • Phase II multiinstitutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
    • Nov 10
    • Piekarz RL, Frye R, Turner M, et al. Phase II multiinstitutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009 Nov 10; 27 (32): 5410-7.
    • (2009) J Clin Oncol , vol.27 , Issue.32 , pp. 5410-5417
    • Piekarz, R.L.1    Frye, R.2    Turner, M.3
  • 37
    • 79952977561 scopus 로고    scopus 로고
    • Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
    • Jun 2
    • Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011 Jun 2; 117 (22): 5827-34.
    • (2011) Blood , vol.117 , Issue.22 , pp. 5827-5834
    • Piekarz, R.L.1    Frye, R.2    Prince, H.M.3
  • 38
    • 18444395839 scopus 로고    scopus 로고
    • Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes
    • DOI 10.1248/bpb.28.124
    • Shiraga T, Tozuka Z, Ishimura R, et al. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull 2005 Jan; 28 (1): 124-9. (Pubitemid 40879796)
    • (2005) Biological and Pharmaceutical Bulletin , vol.28 , Issue.1 , pp. 124-129
    • Shiraga, T.1    Tozuka, Z.2    Ishimura, R.3    Kawamura, A.4    Kagayama, A.5
  • 39
    • 77954879663 scopus 로고    scopus 로고
    • Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma
    • Oct 10
    • Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010 Oct 10; 28 (29): 4485-91.
    • (2010) J Clin Oncol , vol.28 , Issue.29 , pp. 4485-4491
    • Whittaker, S.J.1    Demierre, M.F.2    Kim, E.J.3
  • 40
    • 78951475688 scopus 로고    scopus 로고
    • Final results form a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy [abstract no. 114]
    • Dec 4-7;Orlando (FL)
    • Coiffier B, Pro B, Prince HM, et al. Final results form a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy [abstract no. 114]. 52ndAnnualMeeting and Exposition of the American Society ofHematology; 2010 Dec 4-7;Orlando (FL).
    • (2010) 52ndAnnualMeeting and Exposition of the American Society OfHematology
    • Coiffier, B.1    Pro, B.2    Prince, H.M.3
  • 42
    • 80054031696 scopus 로고    scopus 로고
    • Romidepsin activity in all three disease compartments (skin, blood, lymph nodes) in patients with cutaneous T-cell lymphoma (CTCL) [abstract no. 8047]
    • May 20
    • Kim E, Rook A, Kim Y, et al. Romidepsin activity in all three disease compartments (skin, blood, lymph nodes) in patients with cutaneous T-cell lymphoma (CTCL) [abstract no. 8047]. J Clin Oncol 2010 May 20; 28 (15 Suppl.).
    • (2010) J Clin Oncol , vol.28 , Issue.15 SUPPL.
    • Kim, E.1    Rook, A.2    Kim, Y.3
  • 43
    • 79961151320 scopus 로고    scopus 로고
    • Characterization of cyclic hematologic changes observed in patients with cutaneous T-cell lymphoma (CTCL) receiving romidepsin a novel histone deacetylase (HDAC) inhibitor [abstract no. 3701]
    • Nov 20
    • Whittaker S, Kim EJ, Prince M, et al. Characterization of cyclic hematologic changes observed in patients with cutaneous T-cell lymphoma (CTCL) receiving romidepsin, a novel histone deacetylase (HDAC) inhibitor [abstract no. 3701]. Blood 2009 Nov 20; 114 (22).
    • (2009) Blood , vol.114 , Issue.22
    • Whittaker, S.1    Kim, E.J.2    Prince, M.3
  • 45
    • 70449365376 scopus 로고    scopus 로고
    • Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: A case series report
    • Nov
    • Ritchie D, Piekarz RL, Blombery P, et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 2009 Nov; 94 (11): 1618-22.
    • (2009) Haematologica , vol.94 , Issue.11 , pp. 1618-1622
    • Ritchie, D.1    Piekarz, R.L.2    Blombery, P.3
  • 47
    • 77956522476 scopus 로고    scopus 로고
    • Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin [abstract no. e19533]
    • May 20
    • Cabell C, Bates S, Piekarz R, et al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin [abstract no. e19533]. J Clin Oncol 2009 May 20; 27 (15 Suppl.).
    • (2009) J Clin Oncol , vol.27 , Issue.15 SUPPL.
    • Cabell, C.1    Bates, S.2    Piekarz, R.3
  • 50
    • 67449145358 scopus 로고    scopus 로고
    • Rational combinations usingHDAC inhibitors
    • Jun 15
    • BotsM, Johnstone RW. Rational combinations usingHDAC inhibitors. Clin Cancer Res 2009 Jun 15; 15 (12): 3790-7.
    • (2009) Clin Cancer Res , vol.15 , Issue.12 , pp. 3790-3797
    • Bots, M.1    Johnstone, R.W.2
  • 51
    • 33748451151 scopus 로고    scopus 로고
    • Anticancer activities of histone deacetylase inhibitors
    • DOI 10.1038/nrd2133, PII NRD2133
    • Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006 Sep; 5 (9): 769-84. (Pubitemid 44348499)
    • (2006) Nature Reviews Drug Discovery , vol.5 , Issue.9 , pp. 769-784
    • Bolden, J.E.1    Peart, M.J.2    Johnstone, R.W.3
  • 52
    • 33750463070 scopus 로고    scopus 로고
    • Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines
    • DOI 10.1007/s10637-006-9000-0
    • Kano Y, Akutsu M, Tsunoda S, et al. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs 2007 Feb; 25 (1): 31-40. (Pubitemid 44657640)
    • (2007) Investigational New Drugs , vol.25 , Issue.1 , pp. 31-40
    • Kano, Y.1    Akutsu, M.2    Tsunoda, S.3    Izumi, T.4    Kobayashi, H.5    Mano, H.6    Furukawa, Y.7
  • 53
    • 84892668674 scopus 로고    scopus 로고
    • The combination of histone deacetylase inhibitors and hypomethylating agents exhibits marked synergy in preclinical models of T-cell lymphoma [abstract no. 3937]
    • Nov 19
    • Marchi E, Bongero DC, KalacM, et al. The combination of histone deacetylase inhibitors and hypomethylating agents exhibits marked synergy in preclinical models of T-cell lymphoma [abstract no. 3937]. Blood 2010 Nov 19; 116 (21)
    • (2010) Blood , vol.116 , Issue.21
    • Marchi, E.1    Bongero, D.C.2    Kalac, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.